Phari retweeted
I was in notified by the same insurance company, Blue Cross and Blue Shield of Minnesota that the patient has to fail thalidomide first before receiving Len. So I am now in the year 2002 please RT this so executives at Blue Cross and Blue Shield. See what a bunch of morons they R
Phari retweeted
🚨 TIL therapy is finally breaking through in solid tumors
New review: Evolving TIL therapy in metastatic melanoma
📊 Visual summary below
🔗 Full article: frontiersin.org/journals/imm…
#Oncology #Immunotherapy #Melanoma #CellTherapy #TIL
Phari retweeted
Check our viewpoint published @JAMA_current #MedEd
Abstract Factory—Research Culture Harming Medical Education
The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor.
➡️jamanetwork.com/journals/jam…
@utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG
Phari retweeted
Just out in @NEJM
Effective therapy of extra medullary relapsed myeloma with teclistamab plus talquetamab (Tec-Tal). RedirecTT-1 #ASH25
@myelomaMD @szusmani @mvmateos
80% response rate.
60% PFS at 12 months.
nejm.org/doi/full/10.1056/NE…
@qatarairways Your app or website does not allow one to add American FF number to my booking. What is the value of being one world top tier if we cannot add it seamlessly to Qatar bookings and enjoy your one world partnership?
Phari retweeted
Definitely. ASCT, Early or late, must be considered in all transplant eligible patients
BMT @ASTCT .. please note that as front line transplant for myeloma is used less and less we still discuss collection of cells and offer it to patients.
Phari retweeted
Here are my Top 5 #ASH25 @ASH_hematology myeloma abstracts. #ASH25VR
My Top 5 are based on new data, clinical impact, & methodology with links to the full abstract. Bookmark!
Thread with countdown 👇
Phari retweeted
Truly honoured to be @AACR2025 & speak on #Precision in #RareCancers “A view from India”. Amazing to share the stage with the great @Dr_R_Kurzrock and @youngkwangchae #DART ! @UmutDisel @SGoswamiMDPhD thank you for being the audience! 🙏 @RFhospital @OncoAlert @oncodaily
Phari retweeted
But truly overjoyed and overwhelmed by @AdityaSunavs #OralPresentation #Penpulimab #NPC @Dr_R_Kurzrock @VivekSubbiah @BalazsHalmosMD @ANaingMD @Phari @HeadNeckMD @OncoAlert @oncodaily @OncBrothers #BrotherSisterGoals
Phari retweeted
From Lab to Startup: Dr. Simrit Parmar on Launching Cellenkos youtu.be/TbYwHukA2Ik?si=-WE8… via @YouTube
The world of startups is hard and filled w challenges. The inspiring journey of @spa718 shows tenacity and perseverance that we can all learn from.
My last #HealthcareUnfiltered
Phari retweeted
Thank you @anantm and his colleagues from @EmoryUniversity for this must read - excellent review for clinicians on Artificial Intelligence ascopubs.org/doi/10.1200/OP-… @JCOOP_ASCO @OncoAlert @EthicsdoctorP
Phari retweeted
@niravshahmd presenting CD19.20 CAR-T in DLBCL- a phase 2 registration study with POC manufacturing @MedicalCollege #tandem25
Phari retweeted
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma | Journal for ImmunoTherapy of Cancer @MCWCancerCenter @Chhabra_mayo @Phari jitc.bmj.com/content/13/1/e0…
Phari retweeted
👉#ASH24 wonderful to meet @Phari and Saurabh Chhabra
Dr Hari was my first mentor during internal medicine residency at @MedicalCollege 🙏🏽🙏🏽
Phari retweeted
And of course bumping into our @MedicalCollege crew at ASH-a-Palooza! @Phari and my former co-resident who is now a 2nd year Heme/Onc fellow at @LoyolaOnc #ASH24 #ASHTrainee
Phari retweeted
ash.confex.com/ash/2024/webp…
Excited to share CAR20.19 multicenter data--a nearly 10 year effort. Developed a Phase 1 trial with this construct in 2016, first patient treated at MCW in 2017. Published Phase 1 with target dose, fresh-in/fresh-out CAR cells in Nature Med in 2020.
Phari retweeted
6/ #ASH24 Abstract 931 (Dhakal)
bsAbs and CAR-T are friends, not foes!
Talquetamab bridging before BCMA CAR-T.
@end_myeloma: "Only place where BCMA must precede GPRC5D is dictionary."
In real life, tal's one of the best #MMsm bridging tools we have!
ash.confex.com/ash/2024/webp…
Phari retweeted
Checkmate 067 10 year data 🚨 presented by James Larkin with concurrent @NEJM publication. 10 years of ipi+nivo revolutionizing melanoma care and changing the way we treat cancer!! 10y MSS is >50%! #ESMO24 @OncoAlert nejm.org/doi/abs/10.1056/NEJ…
Phari retweeted
Dara-VRd and Dara-KRd quadruplets as initial therapy for high risk myeloma.
Griffin trial and Master Trial. @nsc_natalie @SusanBal9 @Myeloma_Doc @szusmani @Phari @ninashah33 @tanyawildes
#OpenAccess
nature.com/articles/s41408-0…